IMS Health Holdings (NYSE:IMS) Analyst Rating Consensus

IMS Health Holdings (NYSE:IMS) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.8 by 10 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 4 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. Equity Analysts at the Wells Fargo downgrades the rating on IMS Health Holdings (NYSE:IMS). The brokerage firm has issued a Market Perform rating on the shares. The shares were previously rated Outperform. The rating by the firm was issued on May 12, 2016.

IMS Health Holdings (NYSE:IMS) stock has received a short term price target of $ 32 from 9 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $3.43. The higher estimate of target price is $38 , while the lower price target estimate is $26

IMS Health Holdings (NYSE:IMS) rose 0.12% or 0.03 points on Tuesday and made its way into the gainers of the day. After trading began at $24.94 the stock was seen hitting $24.95 as a peak level and $24.74 as the lowest level. The stock ended up at $24.81. The daily volume was measured at 960,790 shares. The 52-week high of the share price is $33.515 and the 52-week low is $22.36. The company has a market cap of $8,184 million.

IMS Health Holdings, Inc. has lost 1.23% in the last five trading days and dropped 2.71% in the last 4 weeks. IMS Health Holdings, Inc. has dropped 5.27% during the last 3-month period . Year-to-Date the stock performance stands at -2.59%.

IMS Health Holdings, Inc. (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Companys data set contains over 10 petabytes of data and over 500 million patient records. The Company serves healthcare organizations and life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community. The Companys principal offerings include national information offerings, sub-national information offerings, workflow analytics, real-world evidence (RWE) solutions, technology and applications and clinical solutions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *